Effectiveness of amiodarone and electrical cardioversion for chronic rheumatic atrial fibrillation after mitral valve surgery.
Thirty consecutive patients with chronic rheumatic atrial fibrillation (AF) > or = 3 months after successful mitral valve surgery and left atrial diameter < or = 60 mm were treated with oral amiodarone. Protocol included high loading dosages of amiodarone for 4 weeks, and if conversion to sinus rhythm (SR) was not achieved then electrical cardioversion was performed. Patients converted to SR were maintained on low-dose amiodarone for another 4 weeks when treatment was discontinued. Overall, 23 patients (77%) converted to SR after 4 weeks of therapy: 12 (40%) taking amiodarone alone and 11 (37%) with the addition of electrical cardioversion. The duration of AF > 48 months was an adverse factor in the ability to restore SR. Sixteen patients (70%) remained in SR at a mean follow-up of 17 months. The duration of AF < or = 48 months alone or in combination with left atrial diameter < or = 45 mm were the best predictors for long-term maintenance of SR. Thus, short-term amiodarone with or without electrical cardioversion is effective and safe in the treatment of chronic rheumatic AF after mitral valve surgery. The duration of AF and left atrial size can be used to identify patients with successful outcome.
Skoularigis
J
J
Department of Cardiology, Baragwanath Hospital, Johannesburg, South Africa.
Röthlisberger
C
C
Skudicky
D
D
Essop
M R
MR
Wisenbaugh
T
T
Sareli
P
P
D000328:Adult; D000638:Amiodarone / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D002908:Chronic Disease; D003131:Combined Modality Therapy; D004554:Electric Countershock; D015716:Electrocardiography, Ambulatory; D005260:Female; D005500:Follow-Up Studies; D006349:Heart Valve Diseases / Q000601:surgery*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve; D012214:Rheumatic Heart Disease / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
D000638:Amiodarone